|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
To verify their biosuitability, poly(ethylene glycol)-conjugated QDs were linked with human epidermal growth factor receptor 2 (HER2) antibodies for in vitro/in vivo two-photon imaging in HER2-overexpressed MCF7 cells and a xenograft breast tumor model in mice.
|
31840070 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Comparison of the diagnostic score on 50 formaldehyde-fixed paraffin-embedded breast tumor resections by microfluidic versus standard staining showed high concordance (overall agreement: HER2 94%, ER 95.9%, PR 93.6%, Ki67 93.7%) and strong correlation (ρ coefficient: ER 0.89, PR 0.88, Ki67 0.87; p < 0.0001) for all the analyzed markers.
|
31267199 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In pre-clinical models, co-existence of Human Epidermal Growth Factor Receptor-2 (HER2)-amplification and PI3K catalytic subunit (PIK3CA) mutations results in aggressive, anti-HER2 therapy-resistant breast tumors.
|
31219154 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
MEL-18 was exclusively amplified in approximately 30-50% of HER2+ breast tumors and was associated with a favorable clinical outcome (disease-free survival: P = .02 in HER2+ cases, METABRIC; P = .04 in patients receiving trastuzumab).
|
30265336 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Here, we describe the case of trastuzumab, a monoclonal antibody that dramatically improved the life expectancy of women with Erbb2-overexpressing breast tumor, while also raising concerns about a possible incidence of cardiac dysfunction.
|
30887161 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Breast tumor grade (<i>p</i> = 0.0001) and human epidermal growth factor receptor 2 status (<i>p</i> = 0.0262) were also statistically significant.
|
30941234 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We performed IHC studies on breast tumors exposed to hydrochloric acid (HCl) and formic acid (FA) decalcification solutions, and HER2 fluorescence in situ hybridization on a subset of these tumors to establish a protocol for handling bone specimens with suspicion for MBC.
|
28877070 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The aim of this study was to test for the concordance between Her-2/Neu status in the primary breast tumor and corresponding axillary nodal metastases.
|
29750667 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Currently, several HER2 directed antibody-drug conjugates are under clinical investigation for <i>HER2</i> amplified but also HER2 expressing but not amplified breast tumors.
|
30841523 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Its expression was higher in breast tumor tissue than normal tissue (p = 1x10-4), and its expression was significantly higher in HER2 positive than HER2 negative breast tumors in all four cohorts analyzed.
|
31442252 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The HER2-enriched subtype was identified in a substantial proportion of advanced HR+/HER2-negative breast tumors, and was a consistent biomarker of poor prognosis.
|
30679318 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The PKR/eIF2α-P arm is induced by Trastuzumab in sensitive but not resistant HER2+ breast tumors.
|
31086176 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors.
|
31106144 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The tumor to background (T/B) ratio for [<sup>111</sup>In]AC in breast tumors at 2-5 h was correlated to its expression of estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors.
|
29931431 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The ErbB2 receptor tyrosine kinase is overexpressed in approximately 15-20% of breast tumors and associated with aggressive disease and poor clinical outcome. p130Cas represents a nodal scaffold protein regulating cell survival, migration and proliferation in normal and pathological contexts. p130Cas overexpression in ErbB2 human breast cancer correlates with poor prognosis and metastasis formation.
|
30816273 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In conclusion, CD-340-conjugated PLGA nanoparticles containing DOX preferentially delivered encapsulated drug to the breast cancer cells and in breast tumor and reduced the breast tumor cells by apoptosis.
|
31632019 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Histological grade 3 tumors showed a significantly higher MT-1 expression than hitological grade 1 (p < 0.05), while breast tumors negative for estrogen-, progesterone- and HER2- receptors had a significantly higher MT-1 expression than positive breast tumors positive for these parameters (p < 0.05).
|
31092851 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We also found that breast tumors with low ER levels (1-9%), like ER-negative tumors, were mostly GE-HER2-enriched and GE-Basal-like, and more sensitive to NAC than those with high ER levels (≥ 10%).
|
30361874 |
2019 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Human epidermal growth factor receptor-2 (HER-2) overexpression in breast tumor tissues is associated with a poor prognosis but may benefit from treatment with trastuzumab.
|
30661303 |
2019 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
These results all indicate that SPIONs-Cy-PEG-scFv are relevant tumor-targeting magnetic resonance imaging agents, suitable for diagnosis of HER2 overexpressing breast tumor.
|
29466990 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Despite the development of multiple targeted therapies for luminal and HER2+ breast tumors, TNBC lacks specific therapeutic approaches, thus they are treated mainly with radio- and chemotherapy.
|
30234015 |
2018 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We recently established that HRH1 is up-regulated in basal and human epidermal growth factor receptor 2 (HER2)-enriched human breast tumors and that its expression correlates with a worse prognosis.
|
29548821 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
To improve insights into the presence among AR expression, immune cell infiltration and HER2, we analysed HER2-positive breast tumours.
|
30208359 |
2018 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Human epidermal growth factor receptor HER3 (ErbB3), especially in association with its relative HER2 (ErbB2), is known as a key oncogene in breast tumour biology.
|
30367623 |
2018 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Discordances between the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), expression between primary breast tumors and their subsequent brain metastases (BM) were investigated in breast cancer patients.
|
28975433 |
2018 |